Literature DB >> 7572627

Improvement in noninvasive electrophysiologic findings in children after transcatheter atrial septal defect closure.

M H Schenck1, R Sterba, C K Foreman, L A Latson.   

Abstract

To evaluate whether transcatheter closure of secundum atrial septal defects (ASD) affected noninvasive electrophysiologic variables in children, we reviewed the pre-procedural and 1-year postprocedural electrocardiograms and Holter recordings of 18 consecutive children referred for ASD closure. Patients included in the study were a mean of 5.0 years old (SD 1.1) and weighed a mean of 17.9 kg (SD 4.1). ASDs had a mean diameter of 14.0 mm (SD 2.4) and average shunt ratio (pulmonary-to-systemic flow) of 2.1:1. One year after occluder device placement, 9 children (50%) had detectable residual shunts by transthoracic echocardiograms, but only 2 (11%) had shunts that were felt to be possibly significant. One or more fractured occluder legs were noted by chest roentgenogram in 15 patients (83%). Electrocardiograms at follow-up demonstrated improvement in right ventricular dilation in 4 of 7 patients, right atrial enlargement in 3 of 4 patients, and 1 degree atrioventricular block in 2 of 3 patients. Holter recordings showed a decreased incidence of accelerated atrial rhythm in 3 of 7 patients, prolonged junctional escape rhythm in 2 of 2 patients, and premature atrial contractions in 2 of 2 patients. No finding correlated with patient age, defect or occluder diameter, occluder leg fracture(s), or residual defects. These improvements in electrophysiologic abnormalities compare favorably with changes seen 1 year after surgical closure. In conclusion, placement of a transcatheter ASD device in children diminishes noninvasive electrophysiologic abnormalities at 1-year follow-up. By relieving hemodynamic stress caused by an ASD in childhood, a transcatheter device may prevent arrhythmia disturbance later in life.

Entities:  

Mesh:

Year:  1995        PMID: 7572627     DOI: 10.1016/s0002-9149(99)80199-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Interventional cardiology.

Authors:  K P Walsh
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

Review 2.  Atrial Septal Defect and Atrial Fibrillation: The Known and Unknown.

Authors:  George E Blake; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2008-09-16

3.  Transcatheter closure of atrial septal defects using the Cardio-Seal implant.

Authors:  C A Pedra; J Pihkala; K J Lee; C Boutin; D G Nykanen; P R McLaughlin; D A Harrison; R M Freedom; L Benson
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

Review 4.  Catheter closure of secundum atrial septal defects.

Authors:  M P O'Laughlin
Journal:  Tex Heart Inst J       Date:  1997

5.  Early ECG abnormalities associated with transcatheter closure of atrial septal defects using the Amplatzer septal occluder.

Authors:  S L Hill; C I Berul; H T Patel; J Rhodes; S E Supran; Q L Cao; Z M Hijazi
Journal:  J Interv Card Electrophysiol       Date:  2000-10       Impact factor: 1.900

6.  Transcatheter closure of patent foramen ovale using the Amplatzer septal occluder to prevent recurrence of neurological decompression illness in divers.

Authors:  K P Walsh; P T Wilmshurst; W L Morrison
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

7.  Cribriform amplatzer device closure of fenestrated atrial septal defects: feasibility and technical aspects.

Authors:  Mohammed Numan; Amal El Sisi; Magdi Tofeig; Salwa Gendi; Tohami Tohami; Howaida G El-Said
Journal:  Pediatr Cardiol       Date:  2007-11-13       Impact factor: 1.655

8.  Atrioventricular block after ASD closure.

Authors:  Hiroko Asakai; Sofia Weskamp; Lucas Eastaugh; Yves d'Udekem; Andreas Pflaumer
Journal:  Heart Asia       Date:  2016-08-01

9.  Extending the limits of transcatheter closure of atrial septal defects with the double umbrella device (CardioSEAL).

Authors:  R Kaulitz; T Paul; G Hausdorf
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.